The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration [PDF]
Scientific Reports, 2022 To evaluate the sterility, stability, and efficacy of repackaged ziv-aflibercept in 1-mL plastic tuberculin syringes for intravitreal injection after storage for up to 90 days at controlled (4 °C) and ambient (25.8 °C) temperature.
Jakkrit Juhong +8 more
doaj +5 more sources
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage [PDF]
International Journal of Retina and Vitreous, 2020 Background To evaluate the safety and efficacy of intravitreal ziv-aflibercept (IVZ) in the management of vitreous hemorrhage (VH) in eyes with previously lasered proliferative diabetic retinopathy (PDR).
Ahmad M. Mansour +8 more
doaj +5 more sources
Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion [PDF]
Indian Journal of Ophthalmology, 2019 Purpose: To compare the effectiveness of treatment with intravitreal bevacizumab (IVB) and ziv-aflibercept (IVZ) in patients with macular edema (ME) post-branch retinal vein occlusion (BRVO).
Imoro Z Braimah +4 more
doaj +4 more sources
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients [PDF]
BMC Ophthalmology, 2020 Background Myopic choroidal neovascularization (CNV) is the most common sight-threatening complication associated with high myopia. The present study evaluated the efficacy and safety of the intravitreal injection of ziv-aflibercept in patients with ...
Amin E. Nawar, Heba M. Shafik
doaj +5 more sources
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion [PDF]
Clinical Ophthalmology, 2016 Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL ...
Paulose R +4 more
doaj +5 more sources
Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting [PDF]
Clinical Ophthalmology, 2023 Fernando Munayco-Guillén,1,2 Miguel Angel Vazquez-Membrillo,1,2 Marlon Rafael Garcia-Roa,1,2 Jhony Alberto De La Cruz-Vargas,3 Herney Andrés García-Perdomo,4 Rafael Pichardo-Rodriguez3 1Department of Retina and Vitreous Surgery, Instituto Mexicano de ...
Munayco-Guillén F +5 more
doaj +2 more sources
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors [PDF]
Journal for ImmunoTherapy of Cancer, 2022 Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis.
Howard Streicher +13 more
doaj +2 more sources
Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection [PDF]
BMC Ophthalmology, 2022 Background Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept.
Amin E. Nawar +2 more
doaj +2 more sources
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept [PDF]
Indian Journal of OphthalmologyPurpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir +3 more
doaj +2 more sources
Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
Indian Journal of Ophthalmology, 2018 Sumit Randhir Singh, Jay Chhablani
doaj +4 more sources